Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07777614 | OPTIMISE Lung SABR | not yet recruiting | Phase 2 | 208 | Cancer Trials IrelandNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors |
| recruiting |
| Phase 1 / Phase 2 |
| 120 |
| AstraZenecaINDUSTRY |
| 4 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774520 | A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy | recruiting | Phase 2 | 1,173 | Samsung Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | active not recruiting | Phase 2 / Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06514027 | Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations | recruiting | Phase 2 | 30 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | recruiting | Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT07771764 | A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01159288 | Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes(CSET 1437) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02994576 | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer(PRINCEPS) | completed | Phase 2 | 60 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03965468 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC(CHESS) | active not recruiting | Phase 2 | 96 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | recruiting | Phase 1 / Phase 2 | 201 | Yuhan CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05348668 | Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 78 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05466149 | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion | active not recruiting | Phase 2 | 100 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05758116 | Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients | completed | Phase 2 | 5 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06518057 | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06878274 | Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC(RESCUE) | recruiting | Phase 2 | 118 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02971501 | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | active not recruiting | Phase 1 / Phase 2 | 315 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | recruiting | Phase 1 / Phase 2 | 104 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 240 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06007937 | A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04769388 | Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib(FLAME) | completed | Phase 2 | 80 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07697586 | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer | recruiting | Phase 2 | 206 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03392246 | A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | active not recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC(ENCO-BRAF) | active not recruiting | Phase 2 | 119 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06162572 | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 102 | Servier Bio-Innovation LLCINDUSTRY | 14 | Aug 11, 2026 | clinicaltrials |
| NCT06656598 | Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer(SPORADIC) | recruiting | Phase 2 | 152 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07432984 | Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC(FMT-LUNG) | not yet recruiting | Phase 2 | 15 | Se-Hoon LeeOTHER | 0 | Aug 11, 2026 | clinicaltrials |
| NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06161441 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | active not recruiting | Phase 2 | 195 | Regeneron PharmaceuticalsINDUSTRY | 12 | Aug 10, 2026 | clinicaltrials |
| NCT06222489 | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | recruiting | Phase 2 | 16 | The Netherlands Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07590531 | AMT-116 in Combination With AK112 in Patients With Lung Cancer | recruiting | Phase 1 / Phase 2 | 118 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07718737 | Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | not yet recruiting | Phase 2 / Phase 3 | 512 | Multitude Therapeutics Inc.INDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical（Suzhou）Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07746388 | Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial | not yet recruiting | Phase 2 | 30 | University of Maryland, BaltimoreOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT05546866 | Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm | active not recruiting | Phase 2 | 51 | AstraZenecaINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06634056 | Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation(P4-PACIFIC) | recruiting | Phase 2 | 150 | University Health Network, TorontoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750704 | Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC | not yet recruiting | Phase 2 | 153 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03999710 | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials